Alexion to Focus on Rare Disease Therapies by 2030

Alexion, AstraZeneca Rare Disease is setting its sights on a significant expansion of rare disease therapies by 2030, with a substantial portion of its future treatments dedicated to these complex conditions. Dr. Soraya Bekkali, Senior Vice President for Europe, Canada, and International at Alexion, emphasized the company's strategic direction.

"A significant part of the therapies we will introduce by 2030 will concern the area of rare diseases," Dr. Bekkali stated, underscoring the company's dedication to this specialized field. This focus reflects a growing understanding of the unique challenges faced by patients with rare conditions and a commitment to developing innovative solutions.

The company's efforts are geared towards ensuring that patients, regardless of their location or the rarity of their condition, have access to cutting-edge treatments. Alexion aims to be present wherever patients are, addressing critical unmet medical needs through scientific advancement and strategic global reach.

This forward-looking strategy positions Alexion at the forefront of rare disease research and development, signaling a continued investment in improving the lives of individuals affected by these often-debilitating conditions. The company's commitment extends beyond discovery to ensuring broad access to its life-changing therapies.

“

A significant part of the therapies we will introduce by 2030 will concern the area of rare diseases.